Market Place
Sourcing Support
Tevogen Expands CRO Evaluation To Boost Clinical Research
26 Mar 2026 //
GLOBENEWSWIRE
Tevogen Regains Compliance with Nasdaq Minimum Bid Price
25 Mar 2026 //
GLOBENEWSWIRE
Tevogen CIO Mittul Mehta To Present At FabCon 2026
18 Mar 2026 //
GLOBENEWSWIRE
Tevogen Upholds Capital Discipline With Lead Investor Holding
13 Mar 2026 //
GLOBENEWSWIRE
Tevogen.AI Reports Advancements in PredicTcell Beta
13 Mar 2026 //
GLOBENEWSWIRE
Tevogen Appoints Leadership Team For Diversified Growth Strategy
09 Mar 2026 //
GLOBENEWSWIRE
CEO Dr. Ryan Saadi`s Letter to Shareholders
06 Mar 2026 //
GLOBENEWSWIRE
Tevogen Announces Reverse Stock Split
04 Mar 2026 //
GLOBENEWSWIRE
Tevogen To Evaluate Acquisition Of Contract Research Organization
27 Feb 2026 //
GLOBENEWSWIRE
Tevogen Board Considers One-Time Cash Dividend For Shareholders
30 Jan 2026 //
GLOBENEWSWIRE
Tevogen CEO Donates Shares To Aid Local Fire Department
19 Dec 2025 //
GLOBENEWSWIRE
Tevogen CEO Donates 230,000 Shares To Local Law Enforcement
11 Dec 2025 //
GLOBENEWSWIRE
Tevogen Board Member Dr. Curtis Patton Honored By Yale
09 Dec 2025 //
GLOBENEWSWIRE
Tevogen Acknowledged On 2025 NJBIZ Power List For Growth
08 Dec 2025 //
GLOBENEWSWIRE
Tevogen Highlights Capital Efficiency and Low Cash Burn
03 Nov 2025 //
GLOBENEWSWIRE
Tevogen Senior Management Engages With Leaders, Show Progress
29 Oct 2025 //
GLOBENEWSWIRE
Tevogen CIO Mittul to Join Startup Forum at Databricks DATA + AI
10 Sep 2025 //
GLOBENEWSWIRE
Tevogen Forecasts $6.5B Revenue Over 5 Years for Liver Cancer
09 Sep 2025 //
GLOBENEWSWIRE
Tevogen Acknowledges to Yale for Recognizing Dr. Ryan Saadi
26 Aug 2025 //
GLOBENEWSWIRE
Tevogen Reports 72% Rise in Institutional Ownership in Q2 2025
25 Aug 2025 //
GLOBENEWSWIRE
Tevogen CEO Donates Personal Shares to Aid Brain Injury Recovery
18 Aug 2025 //
GLOBENEWSWIRE
Tevogen CEO Donates Personal Shares to Back Local Law Enforcement
18 Aug 2025 //
GLOBENEWSWIRE
Tevogen CEO Affirms Full Protection of Internal Assets
14 Aug 2025 //
GLOBENEWSWIRE
Tevogen.AI, Databrick, Expand PredicTcell Beta in Oncology
13 Aug 2025 //
GLOBENEWSWIRE
Tevogen CEO Confirms Growth, Capital Position, AI Expansion
11 Aug 2025 //
GLOBENEWSWIRE
Tevogen Reports 73% Growth in Institutional Ownership
08 Aug 2025 //
GLOBENEWSWIRE
Tevogen Gets $1 M to Speed Ai Drug Discovery, Stays Well Funded
07 Aug 2025 //
GLOBENEWSWIRE
Tevogen Emphasizes 74% Insider Ownership for Long-Term Vision
30 Jul 2025 //
GLOBENEWSWIRE
Tevogen Opens HQ, CEO-Funded, To Boost R&D and AI
10 Jul 2025 //
GLOBENEWSWIRE
Tevogen CEO Contributes to Build-Out of New Headquarters
30 Jun 2025 //
GLOBENEWSWIRE
Tevogen Advances EBV T Cell Therapy Using AI Insights
18 Jun 2025 //
GLOBENEWSWIRE
Tevogen To Share Updates On Pipeline And Strategy Before Meeting
22 May 2025 //
GLOBENEWSWIRE
Tevogen Bio`s Model Tackles Biopharma Challenges with Innovation
12 May 2025 //
GLOBENEWSWIRE
Tevogen to Share DRS Process Details Amid Shareholder Interest
02 May 2025 //
GLOBENEWSWIRE
CD8 Technology Signs Letter of Intent for Tevogen for Manufacturing
30 Apr 2025 //
GLOBENEWSWIRE
Tevogen CEO to Discuss Liquidity Strategies at BioNJ Conference
29 Apr 2025 //
GLOBENEWSWIRE
Tevogen Explains DRS Vs Brokerage Accounts to Shareholders
29 Apr 2025 //
GLOBENEWSWIRE
Tevogen shares skyrocket as $1B in revenue for oncology pipeline
29 Apr 2025 //
GLOBENEWSWIRE
Tevogen Bio Announces 2025 Annual Meeting
25 Apr 2025 //
GLOBENEWSWIRE
Tevogen Bio Commissions Databricks to Development of PredicTcell
15 Apr 2025 //
GLOBENEWSWIRE
Tevogen CEO to Discuss Liquidity Strategies at BioNJ Conference
14 Apr 2025 //
GLOBENEWSWIRE
Tevogen Bio CEO on NJBIZ 2025 Health Care Power List
26 Mar 2025 //
GLOBENEWSWIRE
Tevogen Bio Reports 600% Higher Market Cap Per Team Member
21 Feb 2025 //
GLOBENEWSWIRE
Tevogen CEO Congratulates RFK Jr. On HHS Secretary Confirmation
13 Feb 2025 //
GLOBENEWSWIRE
Tevogen Bio Tackles Biopharma Challenges With Cost-Efficient Model
10 Feb 2025 //
GLOBENEWSWIRE
Tevogen Highlights ExacTcell™ As Scalable Medical Countermeasure
07 Feb 2025 //
GLOBENEWSWIRE
Tevogen Bio To Receive Up To $10M In Non-Dilutive Grant Funding
28 Jan 2025 //
GLOBENEWSWIRE
Tevogen Bio CEO Congratulates Lynne Patton On Appointment
27 Jan 2025 //
GLOBENEWSWIRE
Tevogen Bio Expands AI Collaboration With Microsoft On Azure
24 Jan 2025 //
GLOBENEWSWIRE
Tevogen Bio Highlights AI-Driven Drug Development At JPM Conference
23 Jan 2025 //
GLOBENEWSWIRE
Tevogen Bio’s Advisory Chair, Professor Sten Vermund, Named USF Dean
14 Aug 2024 //
GLOBENEWSWIRE
Tevogen Bio CEO Reaffirms Growth Strategy, Clarifies S-1 Filing
09 Aug 2024 //
GLOBENEWSWIRE
Tevogen Bio Highlights Achievements And Considers Share Buyback
11 Jul 2024 //
GLOBENEWSWIRE
Tevogen Bio Discusses Unmodified T Cell Tech With Nasdaq`s Ayanian
10 Jul 2024 //
GLOBENEWSWIRE
Ryan Saadi Congratulates Marc Benioff On Yale Award
08 Jul 2024 //
GLOBENEWSWIRE
Tevogen Files Registration Statement for Securities; No New Dilutive Issuances
26 Jun 2024 //
GLOBENEWSWIRE
Tevogen Bio Set to Join Russell 3000® Index
12 Jun 2024 //
GLOBENEWSWIRE
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing
11 Jun 2024 //
GLOBENEWSWIRE
Correction: Tevogen Grateful For Inaugural Listing Event Attendance
07 Jun 2024 //
GLOBENEWSWIRE
Tevogen Bio Expresses Gratitude For Attending Its Inaugural Post-Listing Event
06 Jun 2024 //
GLOBENEWSWIRE
